We work at the interface of biology and engineering to develop new medical devices and human therapies. We create nanoparticles that can deliver genetic therapy inside of cells and even perform genome editing in vivo. We also develop living therapeutics, constructed from human cells and biomaterials, that can provide long-term therapy for chronic diseases like diabetes. Finally, we create smart biomaterials and responsive drug delivery systems that can integrate with the body and provide customized, on-demand treatment for patients.
Latest News
-
Reprogrammed NK immune cells target cancer and autoimmune disorders
A new approach can program these cells inside the body and shows promise against diseases caused by dysfunctional T cells, including lymphoma and autoimmune hepatitis.
-
Anderson and Langer labs launch "living drug factories"
Dan Anderson, Bob Langer, and their former postdoc Omid Veiseh launch Duracyte, a biotechnology company that produces implantable "living drug factories".
-
A new approach to cancer vaccination yields more powerful T cells
Using immune-remodeling mRNA molecules, researchers generated T cells that can slow tumor growth and, in some cases, eradicate tumors.